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ABSTRACT
Objectives: The purpose of this study was to determined the predictive value of maternal serum alpha-fetoprotein (MSAFP) 
as a marker for adverse pregnancy outcomes.
Material and methods: This study was carried out at Dr. Zekai Tahir Burak Women’s Health Education and Research 
Hospital between 2009 and 2010. This study included a total of 1,177 pregnant women, including 170 in the study group 
and 1,007 in the control group. Pregnancy outcomes and characteristics were analyzed with regard to the MSAFP value.
Results: Gestational week, birth weight and APGAR scores were significantly lower in the elevated MSAFP group (p < 0.001). 
Adverse pregnancy outcomes, such as preterm delivery, preterm premature rupture of membranes (PPROM), oligohydram-
nios and intrauterine growth restriction (IUGR) rates were increased in the elevated MSAFP group.
Conclusions: Although ultrasound outweighs as a screening method for neural tube defects and non-invasive prenatal 
testing outweighs for aneuploidy screening MSAFP level in the second trimester is still an important predictor for poor 
maternal/fetal outcomes.
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INTRODUCTION
Alpha-fetoprotein (AFP) is a glycoprotein produced by 
the fetal yolk sac, liver and gastrointestinal system in early 
pregnancy [1]. Traditionally, the measurement of MSAFP has 
been the primary screening test used to identify pregnancies 
at an increased risk of open neural tube defects (NTDs) in 
women without risk factors for NTDs. The American Congress 
of Obstetricians and Gynecologists (ACOG) recommends AFP 
screening for all pregnant women in the second trimester [2]. 
This is one part of the scanning of multiple serum markers, 
usually recommended to be done throughout 15 to 20 weeks 
of pregnancy. In most laboratories, using 2.0–2.5 MoM as the 
upper limit of normal maternal serum AFP level, with a 5% 
false-positivity rate, the detection rate for anencephaly and 
spina bifida is 90% and 80%, respectively [3].
Shortly after the introduction of maternal serum screen-
ing for the diagnosis of fetal abnormalities, adverse preg-
nancy outcomes began to be reported after the detection 
of unexplained isolated elevation of MSAFP [3–5].
When increased maternal AFP levels are found in preg-
nant women with a correct gestational age, normal fetus 
structure and normal amniotic fluid AFP levels, the general 
biological explanation is usually that some damage has 
occurred at the maternal-fetal interface, which results in 
elevated levels of AFP in maternal circulation. In a number 
of studies, using MSAFP cut-off values of 2.0 to 3.0 MoM, 
low birth weight, intrauterine growth retardation (IUGR), 
premature delivery, placental abruption, intrauterine fetal 
death (IUFD), preeclampsia and increased risk of perina-
tal death were found in pregnant women with AFP levels 
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above this value [6–7]. Preeclampsia still remains significant 
cause of maternal and perinatal death, for this reason many 
researchers focused on the prediction of preeclampsia in 
the early stages of the pregnancy and they suggested that 
elevated MSAFP level might be a good predictor for early 
detection of preeclampsia [8].
In recent years, although ultrasound outweighs as 
a screening method for neural tube defects, first trimester 
combined test and non-invasive prenatal testing outweighs 
for aneuploidy screening. MSAFP level in the second trimes-
ter is still an important indicator of pregnancy complications 
as it is easily accessible and cheap [9, 10].
In this study, we aimed to evaluate the association be-
tween unexplained MSAFP elevation in the second trimester 
with pregnancy complications such as preterm labor, pre-
term premature rupture of membranes, preeclampsia, IUGR, 
oligohydramnios, IUFD and placental pathology. 
MATERIAL AND METHODS
This study was carried out at Dr. Zekai Tahir Burak Wom-
en’s Health Education and Research Hospital, Antenatal 
outpatient clinic between 2009 and 2010. The study protocol 
was approved by the local Ethics Committee. The study was 
conducted in accordance with the principles of the World 
Medical Association Declaration of Helsinki. The study in-
cluded primigravida or multiparous pregnant women who 
were admitted in the second trimester with spontaneous 
or in vitro fertilization (IVF) singleton pregnancies who un-
derwent triple screening tests.
Using our hospital’s central immunoassay laboratory 
computer records, the total number of patients who un-
derwent triple blood testing in the second trimester was 
11,654. Of these cases, the study group was composed of 
243 patients in the second trimester (16–20 weeks of ges-
tation) without chromosomal disorders with an adjusted 
MSAFP of ≥ 2.0 MoM for the triple testing which could not 
be explained by multiple pregnancy, fetal abnormality or 
fetomaternal hemorrhage. In the next step, ultrasound re-
sults of these pregnant women detected five twin pregnan-
cies, 13 fetal anomalies and three hematomas. As a result, 
21 pregnant women were excluded from the study group. 
Another 52 women who were admitted to our hospital, but 
were lost to follow-up were also excluded. Thus, in total, 
170 pregnant women with an unexplained elevation of 
MSAFP (≥ 2.0 MoM) detected during triple testing years 
were ıncluded in the study group. 
Pregnant women without fetal anomalies or chromo-
somal disorders whose corrected MSAFP, human chorionic 
gonadotropin (hCG) and unconjugated estriol (uE3) MoM 
values for the triple testing were within normal range during 
the same time period were selected for the control group in 
our study. Those having MSAFP values of 0.75–2.0 MoM, hCG 
of 0.5–2.0 MoM and uE3 of above 0.75 MoM were accepted 
as normal. From 11,654 pregnant women, 6,760 women 
were with normal corrected MoM values for all parameters 
of the triple screening test (MSAFP, hCG and uE3). At least 
seven follow-up visits were performed for each case and 
with a sampling rate of nearly 15%, a total of 1,014 women 
were chosen. Of these 1,014 randomly selected cases, six 
fetal anomalies and one twin pregnancy were detected and 
were excluded from the control group. The total number of 
the control subjects was 1007. This study finally included 
a total of 1,177 pregnant women, including 170 in the study 
group and 1,007 in the control group. 
The gestational age was estimated according to the 
number of days from the date of the last menstrual period 
or by ultrasound. In the initial stage, the pregnant women 
underwent ultrasound examination and the fetal biparietal 
diameter (BPD), femur length (FL) and abdominal circum-
ference (AC) were measured. The results were recorded in 
the triple test form files and venous blood samples were 
drawn from the pregnant women on the same day. Follow-
ing ultracentrifugation, the AFP, hCG and uE3 levels in the 
non-hemolyzed and non-lipemic serum samples were mea-
sured. For the measurement of serum biochemical markers, 
the solid-phase, enzyme-labeled chemiluminescent im-
munometric assay technique was employed using the IM-
MULITE 2000 kits (Siemens Healthcare, Erlangen, Germany) 
(sensitivity: for AFP 0.2 IU/mL, for hCG 0.4 mIU/mL and for 
uE3 0.1 ng/mL). Using the PRISCA Prenatal Risk Calculation 
Software 4.0 program (Siemens Healthcare, Erlangen Ger-
many), the corrected MoM values were calculated according 
to the gestational age, maternal weight, diabetes status, 
race and smoking habits, and a statistical risk assessment 
was made for trisomy 21, trisomy 18 and NTD. In the next 
step, all pregnant women were examined by ultrasound to 
evaluate fetal abnormalities, chromosomal abnormalities 
and the presence of fetomaternal hemorrhage.
In this study, the upper limit of MSAFP MoM, adjusted 
according to the gestational age, maternal weight, smoking 
habits and diabetes status, was accepted as 2.0 MoM [11].
Data including age, gravida, parity, the number of live 
births, abortus and curettage, weight, smoking and drug his-
tory, gestational diabetes mellitus (GDM) status, IVF, amnio-
centesis, threatened abortion and threatened preterm labor 
of 1,177 pregnant women were retrospectively collected 
from the case files or via phone calls with the patients. Gesta-
tional age, mode of delivery, sex of infant, one and five-min 
Appearance, Pulse, Grimace, Activity, Respiration (APGAR) 
scores and newborn intensive care needs were assessed.
With the exception of cases of IUFD, those infants hav-
ing one and five-min APGAR scores above 7 were accepted 
as normal, while those with APGAR scores below 7 were 
considered to be abnormal. 
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Pregnancy complications involved preterm delivery 
(delivery before 37 weeks of gestation), PPROM (mem-
brane rupture before 37 weeks of gestation and onset of 
the uterine concractions, oligohydroamnios (amniotic fluid 
index ≤ 5), preeclampsia (new onset of hypertension and 
either proteinuria or end-organ dysfunction after 20 weeks 
of gestation in a previously normotensive woman) and IUGR 
(estimated fetal weight < 10th percentile).
A normal pregnancy outcome was defined as birth of 
a baby after the 37th week, with birth weight being in the 
10 percentile according to the gestational age, following 
a pregnancy free from complications.
Statistical analysis
The descriptive statistics for continuous variables were 
expressed in mean ± standard deviation or median (mini-
mum–maximum), while nominal variables were expressed 
in the number and percentage (%). The significance of the 
difference between the mean values of the groups was 
evaluated using the Student’s t-test, while the significance 
of the difference in the median values was evaluated using 
the Mann-Whitney U test. Whether or not AFP had a sta-
tistical significant effect on the occurrence of pregnancy 
complications was assessed using the Pearson’s chi-square 
or Fisher’s exact outcome chi-square tests. For the emer-
gence of any pregnancy complication related to AFP, the 
odds ratio (95% confidence interval [CI]) was calculated. For 
the prediction of IUFD related to AFP, sensitivity, specificity 
and positive predictive values (PPVs) and negative predictive 
values (NPVs) were also calculated. A p value of < 0.05 was 
considered statistically significant. Statistical analysis was 
performed using SPSS for Windows version 17 software 
(SPSS Inc., Chicago, IL, USA).
RESULTS
In the study group, the unexplained elevated MSAFP 
levels (≥ 2 MoM) in the 170 pregnant women in the second 
trimester triple test were examined. In the control group, 
1,007 pregnant women were evaluated and all parameters 
of the second trimester triple test were found to be normal 
and without fetal or chromosomal anomalies.
The demographic characteristics of the unexplained el-
evated MSAFP and control groups are shown in Table 1. The 
demographic characteristics of the patients were not sig-
nificantly different statistically.
The distribution of neonatal outcomes and obstetric 
characteristics of the unexplained elevated MSAFP and 
control groups can be seen in Table 2.
The mean gestational age at birth was 35.1 ± 6.5 weeks in 
the unexplained elevated MSAFP group and 38.7 ± 2.3 weeks in 
the control group. The gestational age of the study group was 
significantly lower, compared to the control group (p < 0.001). 
The mean birth weight was 2,930 g in the unexplained 
elevated MSAFP group and 3,300 g in the control group. 
The birth weight in the study group was significantly lower 
than in the control group (p < 0.001).
The offsprings of 37 women (21.8%) in the elevated 
MSAFP group, compared to those of 63 (6.3%) in the control 
Table 1. Demographic characteristics of the elevated MSAFP  
and control groups
Variables
MSAFP ≥ 2 
MoM
(n = 170)
MSAFP < 2 
MoM
(n = 1007)
p value
Age 27.1 ± 5.8 26.7 ± 5.2 0.435 
Gravida 2 (1–13) 2 (1–9) 0.452
Parity 1 (0–5) 1 (0–4) 0.351
Live births 1 (0–10) 1 (0–4) 0.556
Abortus 0 (0–8) 0 (0–8) 0.926
D & C 0 (0–7) 0 (0–6) 0.196
Smoking history 14 (8.2%) 77 (7.6%) 0.790 
Maternal weight [kg] 64.5 ± 11.4 64.5 ± 11.3 0.959
IVF 3 (1.8%) 16 (1.6%) 0.747
DM 9 (5.3%) 31 (3.1%) 0.140
D & C — dilatation and curettage; DM — diabetes mellitus; IVF — in vitro 
fertilization
Table 2. Elevated MSAFP and control group obstetric characteristics 
and neonatal outcomes
Variables
MSAFP ≥ 2 
MoM
(n = 170)
MSAFP < 2 
MoM
(n = 1007)
p value
Weeks at birth 35.1 ± 6.5 38.7 ± 2.3 < 0.001
Mode of delivery 0.096 
Normal 60.0% (n = 102)
53.1% 
(n = 535)
C/S 40.0% (n = 68)
46.9% 
(n = 472)
Birth weight [g] 2930(560–4490)
3300 
(288–5040) < 0.001
Sex of child 0.588
Female 47.1% (n = 80)
49.3% 
(n = 496)
Male 52.9% (n = 90)
50.7% 
(n = 510)
NICU required 21.8% (n = 37)
6.3% 
(n = 63) < 0.001
APGAR < 0.001
Normal 75.9% (n = 129)
98.7% 
(n = 993)
Low 6.5% (n = 11)
0.6% 
(n = 6)
APGAR — Appearance, Pulse, Grimace, Activity, Respiration;  
C/S — cesarean section; ICU — intensive care unit
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group, were referred to the intensive care unit. The study 
group statistically significantly increased the need for the 
NICU (p < 0.001).
In the unexplained elevated MSAFP group, 129 infants 
had normal APGAR scores, while 11 (6.5%) had low APGAR 
scores and IUFD occurred in 30 (17.6%). In the control group, 
these rates were 993 (98.7%) had normal APGAR scores, 
6 had low APGAR scores (0.6%) and 7 IUFD occurred (0.7%). 
The offsprings with low APGAR scores and the IUFD cases 
in the study group were significantly higher, compared to 
the control group (p < 0.001).
The pregnancies of 29 women in the unexplained el-
evated MSAFP group and 36 in the control group were 
complicated by preterm births. The high risk of occurrence of 
preterm delivery in the study group was statistically signifi-
cant compared to the control group, with an odds ratio (OR) 
of 5.547 (95% CI 3.298–9.331; p < 0.001). In the unexplained 
elevated MSAFP group, 13 out of 36 pregnant women had 
preterm births caused by preterm premature rupture of 
membranes (PPROM), while in the control group, 18 out of 
29 preterm births were due to PPROM. 
Preterm premature rupture of membranes was observed 
in 13 pregnant women in the unexplained elevated MSAFP 
group and 18 in the control group, indicating a significantly 
higher risk for developing PPROM in the study group with 
an OR of 4.550 (95% CI 2.186–9.469; p < 0.001).
Oligohydramnios was detected in 31 pregnant women in 
the unexplained elevated MSAFP group and 58 in the control 
group. Upon detection in these cases, the accompanying 
intrauterine growth restriction (IUGR) was evaluated in the 
10 out of these 31 women in the unexplained elevated MSAFP 
group and in the 12 out of 58 in the control group. Isolated 
oligohydramnios was present in 21 pregnant women in the 
unexplained elevated MSAFP group and in 46 women in the 
control group. Compared to the control group, the risk of 
oligohydramnios was significantly higher in the study group 
with an OR of 2.944 (95% CI 1.709–5.074; p < 0.001).
Preeclampsia complications were present in five preg-
nant women in the unexplained elevated MSAFP group and 
23 in the control group. In terms of preeclampsia, there was 
no statistically significant difference between the groups 
with an OR of 1.296 (95% CI 0.486–3.458; p = 0.586).
The presence of IUGR complications was found in 
24 women in the study group and 35 in the control group. 
Compared to the control group, the risk of IUGR was found 
to be significantly higher in the study group with an OR of 
4.565 (95% CI 2.640–7.895; p < 0.001).
In addition, 91 women in the unexplained elevated 
MSAFP group and 138 in the control group experienced any 
type of pregnancy complication. Compared to the control 
group, the risk of developing any type of pregnancy compli-
cation increased by 7.2-fold in the study group with an OR 
of 7.254 (95% CI 5.107–10.302; p < 0.001). 
The AFP-related sensitivity, specificity, PPVs and NPVs 
for prediction of adverse pregnancy outcomes are shown in 
Table 4. The preterm birth prediction for AFP was found to 
be 44.6% for sensitivity, 87.3% for specificity, 17.1% for PPV 
and 96.4% for NPV. The IUGR prediction for AFP was found 
to be 40.7% for sensitivity, 86.9% for specificity, 14.1% for 
PPV and 96.5% for NPV. The AFP-related IUFD prediction for 
sensitivity was 67.9% with 86.9% specificity, 11.2% PPV and 
99.1% NPV. The AFP prediction for oligohydramnios sensitiv-
Table 3. High MSAFP values (≥ 2.0 MoM) in relation to pregnancy complications
Pregnancy complications Present Absent p values Odds ratio (95% CI)
Preterm delivery
AFP ≥ 2 MoM 29 (47.1%) 141 (12.7%) 0.001 5.547 (3.298–9.331)
AFP < 2 MoM 36 (52.9%) 971 (87.3%) – 1.000
PPROM
AFP ≥ 2 MoM 13 (41.9%) 157 (13.7%)  0.001 4.550 (2.186–9.469)
AFP < 2 MoM 18 (58.1%) 989 (86.3%) – 1.000
Oligohydramnios 
AFP ≥ 2 MoM 21 (31.3%) 49 (13.4%)  0.001 2.944 (1.709–5.074)
AFP < 2 MoM 46 (68.7%) 961 (86.6%) – 1.000
Preeclampsia
AFP ≥ 2 MoM 5 (17.9%) 165 (14.4%) 0.586 1.296 (0.486–3.458)
AFP < 2 MoM 23 (82.1%) 984 (85.6%) – 1.000
IUGR
AFP ≥ 2 MoM 24 (40.7%) 146 (13.1%) 0.001 4.565 (2.640–7.895)
AFP < 2 MoM 35 (59.3%) 972 (86.9%) – 1.000
IUGR — intrauterine growth restriction; PPROM — preterm premature rupture of membranes
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ity was found to be 31.3% with 86.6% specificity, 12.4% PPV 
and 95.4% NPV. The PPROM prediction for AFP sensitivity 
was found to be 41.9% with 86.3% specificity, 7.6% PPV and 
98.2% NPV. In the prediction of preeclampsia, AFP sensitivity 
was found to be 17.9% with 85.6% specificity, 2.9% PPV and 
97.7% NPV. In the prediction of any pregnancy complica-
tions, AFP sensitivity was 39.7% with 91.7% specificity, 53.5% 
PPV and 86.3% NPV (Table 4).
DISCUSSION
The maternal serum alpha-fetoprotein (MSAFP) levels, 
other than for NTD screening, with β-hCG and uE3 (trisomy) 
screening tests in the second trimester are included in the 
antenatal care protocol [7]. Several studies have shown that 
MSAFP levels of ≥ 2 MoM in the second trimester, except 
from cases of multiple gestation or fetal anomalies, are 
associated with an increased risk of preeclampsia, IUGR, 
preterm delivery, placental abruption and fetal loss [12, 13]. 
The result of this study showed that unexplained maternal 
serum AFP levels in the second trimester of pregnancy is 
related with maternal, fetal and neonatal complications. 
To determine the optimal AFP cut-off value, in their 
meta-analysis, Yuan et al. [14] carried out a systematic study 
of the relationship between elevated second trimester 
MSAFP in the general population and preterm delivery. 
The study examined a total of 207,135 women in 24 stud-
ies published between the years 1991 and 2007 including 
14 population-based studies and 10 comparative case-con-
trol studies. Fourteen of the studies used 2.0 MoM as the 
elevated AFP level, while eight studies used 2.5 MoM as 
the cut-off value. In our study evaluating the association 
between unexplained MSAFP elevation and pregnancy 
complications, we used the cut-off value for unexplained 
MSAFP as ≥ 2 MoM, which significantly increased the risk of 
pregnancy complications such as preterm delivery, PPROM, 
IUGR and oligohydramnios in the pregnant women. 
Morris et al. performed a systematic meta-analysis of 
cohort studies evaluating second trimester markers and 
preeclampsia. There was significant variation among studies 
in the threshold used to identify patients at high-risk as well 
as significant variation in screening performance. The most 
effective thresholds were 2.0 multiples of the median (MoM) 
for alpha-fetoprotein (AFP) resulting in a positive likelihood 
ratio (LR) of 2.36 and a negative likelihood ratio of 0.96 [15]. 
On the other hand Davidson, Kang and Wald did not find 
any significant increase in MSAFP levels in preeclamptic 
women [8, 16, 17]. We found no significant difference in 
the rate of preeclampsia between the groups. The relatively 
small sample size of the preeclampsia in the elevated MSAFP 
group is a limitation of this study.
Katz et al. [18] in the compilation of their publications, 
found that after excluding anomalies evaluated by ultra-
sound and/or amniocentesis, elevated MSAFP, preterm de-
livery and IUGR were associated with a 2 to 4-fold increase 
in the risk of giving birth to a low-birth weight baby. Mean-
while, unexplained elevated AFP levels (2.0–3.0 MoM) were 
associated with a 10-fold increase in placental abruption 
and perinatal mortality. The results obtained from the scans 
of 225,000 pregnant women showed that 20 to 38% of the 
women with unexplained MSAFP elevation had poor preg-
nancy outcomes. Similarly, our study results are consistent 
with the previous findings. 
In a prospective, multi-center, cohort study Smith et al. [19] 
evaluated 8,483 pregnant women attending a prenatal pro-
gram in Scotland over a two-year period. The patients were 
examined for the relationship between MSAFP levels and 
adverse perinatal outcome. In women with a high MSAFP 
level, a statistically significant increased risk of preterm birth 
with an OR of 2.1 and stillbirth with an OR of 4.4 was found. 
These values are also consistent with our findings. 
In another study, Anfuso et al. [20] conducted a retro-
spective cohort study of pregnant women having unex-
plained high MSAFP levels (≥ 2.5 MoM) due to any visible 
cause and compared them to women with normal MSAFP 
levels. They were found to have a 5.8-fold increased risk of 
preterm birth, a 15.2-fold increased risk of PRROM, a 2.6-fold 
increased risk of preeclampsia/HELLP syndrome, a 5.9-fold 
increased risk of IUGR and a significantly increased risk of 
IUFD. Similarly, in our study, we identified the risks of pre-
term delivery, PPROM, IUGR and IUFD to be significantly 
increased. However, unlike Anfuso et al. we were unable 
to find any statistically significant difference in terms of 
preeclampsia between the control and the study groups. 
CONCLUSIONS
In conclusion, our study results showed that unex-
plained second trimester MSAFP elevation was significantly 
associated with poor maternal/fetal outcomes. In patients 
Table 4. AFP-related sensitivity, specificity and PPVs and NPVs for 
pregnancy complications
Variables Sensitivity Specificity PPV NPV
Preterm delivery 44.6% 87.3% 17.1% 96.4%
IUGR 40.7% 86.9% 14.1% 96.5%
IUFD 67.9% 86.9% 11.2% 99.1%
Oligohydramnios 31.3% 86.6% 12.4% 95.4%
PPROM 41.9% 86.3% 7.6% 98.2%
Preeclampsia 17.9% 85.6% 2.9% 97.7%
Adverse perinatal 
outcomes 39.7% 91.7% 53.5% 86.3%
IUFD — intrauterine fetal death; IUGR — intrauterine growth restriction; 
NPV — negative predictive value; PPROM — preterm premature rupture of 
membranes; PPV — positive predictive value
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where the fetus is structurally normal, elevated MSAFP in-
dicates a defect in the placentation.
Although unexplained high MSAFP values are associat-
ed with an increased risk of pregnancy complications, there 
is no consensus on the need for the observation of these 
pregnant women or on the methods to be implemented 
for monitoring these patients. Due to the low sensitivity of 
MSAFP and its PPV, its use alone as a screening test to predict 
pregnancy complications can be considered appropriate. 
Therefore, these pregnant women should be under close 
clinical follow-up and auxiliary testing should be carried 
out to improve maternal/fetal outcome and, eventually, to 
reduce perinatal mortality and morbidity. Furthermore, AFP 
with other serum markers, particularly hCG, in combination 
with uterine artery Doppler analysis can increase the recog-
nition of pregnancy complications in women. In addition, 
detailed pathological examination of the placenta following 
delivery can provide further information about the cause of 
MSAFP elevation.
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